- Adult:
-
NSAIA w/ analgesic and antipyretic action:
- moderate to Severe OA,
RA,
AS:
- 25mg PO bid/tid, incr dose at weekly intervals to max of 150-200 mg/day;
- if SR capsule is used, initial dose is 75mg qd;
- extended release caps: 75 mg PO qam or qpm, may increase to 75 mg PO bid, w/ max of 200 mg PO/day;
- shoulder bursitis/tendinitis: 25-50mg PO tid (usual duration of therapy is 7-14 days);
- acute
Gouty Arthritis: 50mg PO tid initially, then taper off gradually;
- supplied: caps: 25, 50 mg; caps extended release: 75 mg;
- often causes GI upset and in some cases
PUD
- administer capsule immediately after meals or with antacids and consider prophylactic use of
anti-ulcer agents;
- Peds:
- not recommended for children less than 14yrs except for neonates with patent ductus arteriosus;
- Precautions:
- contraindicated w/ Syndrome of nasal polyps, angioedema, or bronchospastic reaction to asprin and other
NSAIA;
- contraindicated with active GI bleeding or h/o recurrent GI lesions;
- contraindicated w/ use of
Lithium (may result in lithium toxicity);
- use with caution in patients with renal or hepatic insufficiency, bleeding disorders (inhibition of platlet aggregation),
parkinsonism, depression, epilepsy, psychiatric disturbances (worsening of symptoms);
Longterm treatment with nonsteroidal antiinflammatory drugs in rheumatoid arthritis: a prospective drug survival study.
The use of indomethacin to prevent the formation of heterotopic bone after total hip replacement. A randomized, double-blind clinical trial.
Time-Dependent Inhibitory Effects of Indomethacin on Spinal Fusion.
